Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep 3;8(9):88.
doi: 10.1038/s41408-018-0122-3.

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib

Oliver Ottmann  1 , Giuseppe Saglio  2 , Jane F Apperley  3 , Christopher Arthur  4 , Eduardo Bullorsky  5 , Aude Charbonnier  6 , John F Dipersio  7 , Hagop Kantarjian  8 , Hanna Jean Khoury  9 , Dong-Wook Kim  10 , Diane Healey  11 , Lewis Strauss  11 , Jorge E Cortes  8
Affiliations

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib

Oliver Ottmann et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

O.O. has acted as a consultant, advisor, or speaker for ARIAD, Bristol-Myers Squibb, Celgene, Fusion Pharma, Novartis, Pfizer, Roche, and SUN Pharma. G.S. has acted as a consultant and a speaker for ARIAD, Bristol-Myers Squibb, Novartis, and Pfizer. J.F.A. is an NIHR Senior Investigator and acknowledges the support of the Imperial College NIHR Biomedical Research Centre and has acted as a consultant, speaker, and advisor for ARIAD, Bristol-Myers Squibb, Incyte, Novartis, Pfizer, and SUN Pharma. C.A. has served on advisory boards and acted as a speaker for ARIAD, Bristol-Myers Squibb, Novartis, and Pfizer. E.B. has no disclosures to declare. A.C. has served on advisory boards and has acted as a speaker for Bristol-Myers Squibb, Incyte, Novartis, and Pfizer. J.F.D. has no disclosures to declare. H.K. has served on advisory boards for ARIAD, Bristol-Myers Squibb, Novartis, and Pfizer. H.J.K. has no disclosures to declare. D.-W.K. has received research funding from and served on an advisory committee for Bristol-Myers Squibb. D.H. and L.S. are employees of Bristol-Myers Squibb. J.C. has served as a consultant to and received research funding from ARIAD, Bristol-Myers Squibb, Novartis, Pfizer, and Teva.

Figures

Fig. 1
Fig. 1. Efficacy outcomes for patients with CML-AP by dosing schedule.
a Duration of MaHR for patients who achieved MaHR, b PFS, and c OS are shown for the QD (solid lines) and BID (dashed lines) dosing groups. Efficacy analyses were conducted in the intention-to-treat population of patients. BID twice a day, CI confidence interval, MaHR major hematologic response, NA not available, OS overall survival, PFS progression-free survival, QD once a day
See this image and copyright information in PMC

References

    1. Sasaki K, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015;2:e186–e193. doi: 10.1016/S2352-3026(15)00048-4. - DOI - PMC - PubMed
    1. Ohanian M, et al. Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. Clin. Lymphoma Myeloma Leuk. 2014;14:155–162. doi: 10.1016/j.clml.2013.08.008. - DOI - PMC - PubMed
    1. Rea D, et al. First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia. Leukemia. 2012;26:2254–2259. doi: 10.1038/leu.2012.92. - DOI - PubMed
    1. Kantarjian H, et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood. 2009;113:6322–6329. doi: 10.1182/blood-2008-11-186817. - DOI - PMC - PubMed
    1. Radich J. Major progress in understanding progression in chronic myeloid leukemia. J. Exp. Med. 2015;212:1482. doi: 10.1084/jem.21210insight1. - DOI - PMC - PubMed

MeSH terms